2/2: IMPACt-LBP DCC
2/2: IMPACt-LBP DCC
批准号:
10092312
负责人:
Hrishikesh Chakraborty
金额:
$62.01万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-15 至 2026-06-30
关键词:
AddressAgeAmbulatory CareAmericanAmerican College of PhysiciansCaringCategoriesChronic low back painClinicClinicalClinical ResearchClinical Trials Data Monitoring CommitteesClinical Trials DesignClinical trial protocol documentCluster randomized trialCollaborationsDataData CollectionData Coordinating CenterData SetDoctor of ChiropracticEnsureEpidural InjectionsEvaluationExerciseFeasibility StudiesFoundationsFutureGoalsGuidelinesHealth Care CostsHealth systemHealthcare SystemsInfrastructureInterventionIowaLeadLinkLow Back PainManuscriptsMedicalMedical Care CostsMedical centerMethodsModelingMonitorMusculoskeletalMusculoskeletal PainNon-Steroidal Anti-Inflammatory AgentsOnline SystemsOpioidOrganizational PolicyOutcomePainPain interferencePain managementPain qualityPatient CarePatientsPhasePhysical FunctionPhysiciansPilot ProjectsPoliciesPreparationProceduresProcessProviderPublicationsRandomized Clinical TrialsReportingResearch InstituteResearch PersonnelResourcesRiskSafetySourceSpinal FusionSpinal ManipulationStatistical Data InterpretationSystemTechniquesTimeTrainingUniversitiesVisitWorkbasecare providerschronic paincollaborative carecommunity based participatory researchcomparative effectivenesscompare effectivenesscostdata disseminationdata managementdata qualitydesigndisabilitydisability impacteffectiveness evaluationelectronic data capture systemexperiencehealth care service utilizationimplementation facilitationimplementation trialimprovedinnovationmeetingsmembermultidisciplinaryopioid epidemicopioid mortalityopioid usepain patientpain reductionphysical therapistpragmatic trialprescription opioidpublic repositorysecondary endpointservice utilizationstandard caretreatment as usualweb site
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Low back pain (LBP) is a key source of medical costs and disability, impacting over 31 million Americans at
any given time and resulting in $100-$200 billion per year in total healthcare costs. LBP is one of the leading
causes of ambulatory care visits to US physicians; unfortunately, these visits often result in treatments such as
opioids that can lead to more harm than benefit. In 2017 the American College of Physicians (ACP) guideline
for LBP recommended patients receive non-pharmacological interventions as a first-line treatment but stopped
short of offering solutions regarding how such treatments should be integrated into routine patient care.
Roadmaps exist for multi-disciplinary collaborative care that includes doctors of chiropractic and physical
therapists, well-trained primary contact clinicians with specific expertise in the treatment of musculoskeletal
conditions, as first line providers for LBP. These clinicians routinely employ many of the non-pharmacological
approaches recommended by the ACP guideline, including spinal manipulation and exercise. Important
foundational work conducted by members of the study team has demonstrated that such care is feasible, safe,
and results in improved physical function, less pain, fewer opioid prescriptions, and reduced utilization of
healthcare services. However, this treatment approach for LBP has yet to be widely implemented or validated
using rigorous scientific methods. Our overarching goal is to refine and implement a multidisciplinary
collaborative care model for LBP (MC2LBP) in 3 academic Health Care Systems (HCS) and then evaluate its
effectiveness by comparing it to usual medical care in patients age 18 and older suffering from LBP.
Completion of project study aims will begin with a one-year UG3 planning phase involving completion of 22
milestones in 2 categories of phased activities - model implementation and clinical trial design. UH3 study aims
will be accomplished using a pragmatic, cluster-randomized, clinical trial design. The study will be managed
through a Clinical Coordinating Center and Data Coordinating Center, both housed at the Duke Clinical
Research Institute, in collaboration with Dartmouth-Hitchcock Medical Center and the University of Iowa.
During the planning phase, we will build implementation infrastructure across three HCS, finalize the clinical
trial protocol, and complete the tasks necessary to transition from the UG3 to UH3 phase. The UH3 phase will
be used to: 1) Operationalize the integration of new organizational policies and procedures required to facilitate
implementation of MC2LBP at intervention clinics; 2) Determine the comparative effectiveness of MC2LBP vs
usual care; 3) Estimate and compare medical resource use and costs of implementing MC2LBP; and 4)
Evaluate patient, provider, system and policy level barriers and facilitators to implementing MC2LBP, using a
mixed method, process evaluation approach. Results from this study have the potential to inform future
implementation and policy efforts to improve the quality of pain management for patients suffering from LBP
while simultaneously reducing opioid prescriptions, health care costs and utilization of services.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:10827791
-
项目类别:
-
资助金额:$351.09万
-
财政年份:2023
-
负责人:Hrishikesh Chakraborty
-
依托单位:
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:10557379
-
项目类别:
-
资助金额:$13.59万
-
财政年份:2022
-
负责人:Hrishikesh Chakraborty
-
依托单位:
2/2: IMPACt-LBP DCC
-
批准号:10447570
-
项目类别:
-
资助金额:$68.98万
-
财政年份:2021
-
负责人:Hrishikesh Chakraborty
-
依托单位:
Biomarkers of Dietary Intake and Exposure Data Coordinating Center
-
批准号:10649583
-
项目类别:
-
资助金额:$43.98万
-
财政年份:2021
-
负责人:Hrishikesh Chakraborty
-
依托单位:
Biomarkers of Dietary Intake and Exposure Data Coordinating Center
-
批准号:10286935
-
项目类别:
-
资助金额:$56.35万
-
财政年份:2021
-
负责人:Hrishikesh Chakraborty
-
依托单位:
Biomarkers of Dietary Intake and Exposure Data Coordinating Center
-
批准号:10461148
-
项目类别:
-
资助金额:$55.35万
-
财政年份:2021
-
负责人:Hrishikesh Chakraborty
-
依托单位:
2/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension-DCC
-
批准号:10214114
-
项目类别:
-
资助金额:$93.54万
-
财政年份:2021
-
负责人:Hrishikesh Chakraborty
-
依托单位:
2/2: IMPACt-LBP DCC
-
批准号:10653129
-
项目类别:
-
资助金额:$71.33万
-
财政年份:2021
-
负责人:Hrishikesh Chakraborty
-
依托单位:
2/2 Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension-DCC
-
批准号:10486005
-
项目类别:
-
资助金额:$91.77万
-
财政年份:2021
-
负责人:Hrishikesh Chakraborty
-
依托单位:
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:10418650
-
项目类别:
-
资助金额:$142.37万
-
财政年份:2018
-
负责人:Hrishikesh Chakraborty
-
依托单位:
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:10336157
-
项目类别:
-
资助金额:$29.6万
-
财政年份:2018
-
负责人:Hrishikesh Chakraborty
-
依托单位:
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:10554481
-
项目类别:
-
资助金额:$31.18万
-
财政年份:2018
-
负责人:Hrishikesh Chakraborty
-
依托单位:
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:10174992
-
项目类别:
-
资助金额:$157.27万
-
财政年份:2018
-
负责人:Hrishikesh Chakraborty
-
依托单位:
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:10330314
-
项目类别:
-
资助金额:$36.74万
-
财政年份:2018
-
负责人:Hrishikesh Chakraborty
-
依托单位:
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:9791195
-
项目类别:
-
资助金额:$97.54万
-
财政年份:2018
-
负责人:Hrishikesh Chakraborty
-
依托单位:
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:10625035
-
项目类别:
-
资助金额:$72.95万
-
财政年份:2018
-
负责人:Hrishikesh Chakraborty
-
依托单位:
The IGNITE II CC: Engagement, Coordination, Demonstration, and Dissemination
-
批准号:10320544
-
项目类别:
-
资助金额:$14.13万
-
财政年份:2018
-
负责人:Hrishikesh Chakraborty
-
依托单位:
SPIRRIT-HFPEF - DCC
-
批准号:10188597
-
项目类别:
-
资助金额:$22.17万
-
财政年份:2017
-
负责人:Hrishikesh Chakraborty
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: